Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0241908 (
BFH
)
20
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Benign familial hematuria
(
BFH
) is characterized by autosomal dominant inheritance, thinning of the glomerular basement membrane (GBM) and normal renal function. It is frequent in patients with persistent microscopic hematuria, but cannot be clinically differentiated from the initial stages of Alport syndrome, a severe GBM disorder which progresses to renal failure. We present here linkage of benign familial hematuria with the COL4A3 and
COL4A4
genes at 2q35-37 (Zmax = 3.58 at theta = 0.0). Subsequently, a glycine to glutamic acid substitution was identified in the collagenous region of the
COL4A4
gene. We conclude that type IV collagen defects cause both benign hematuria and Alport syndrome. Furthermore, our data suggest that
BFH
patients can be carriers of autosomal recessive Alport syndrome.
...
PMID:Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. 878 73
Benign familial hematuria
(
BFH
: MIM141200) is an autosomal-dominant disease accounting for one-fifth of all hematuria of unknown cause in children. Previous observations suggest that
BFH
may be allelic to recessive Alport syndrome (AS: MIM 203780) with a mutation in the COL4A3/
COL4A4
locus. However, it is not clear whether all cases of
BFH
are due to heterozygous mutation of COL4A3/
COL4A4
genes. We report here the exclusion of linkage between
BFH
and COL4A3/
COL4A4
loci at 2q35-37 in a restricted population from Sicily (Italy). Total lod score is -9.6 at theta 0. Furthermore, in some cases exclusion of linkage is evident even considering single families. We conclude that
BFH
is genetically heterogeneous.
...
PMID:Evidence for genetic heterogeneity in benign familial hematuria. 1046 Sep 35